Non-Responders and the Limits of Ayurvedic Treatment in HS

Why Honest Limits Matter

The tendency in any therapeutic tradition is to emphasise what it can achieve. This is understandable — practitioners develop genuine confidence in their approach through observed results, and that confidence shapes how they communicate about treatment. But when this emphasis on capability is not accompanied by equal clarity about limitation, it produces a specific kind of harm: patients who are not suitable candidates continue treatment for longer than is clinically justified, delaying their access to approaches that might serve them better, and accumulating frustration and expense in the process.

Ayurvedic treatment for HS — including the EPOH Protocol — works through internal correction of the systemic drivers of HS activity. It addresses gut dysfunction, hormonal imbalance, metabolic dysregulation, and immune irregularity in a structured, phase-based sequence. For a significant proportion of HS patients, this approach produces meaningful and durable improvement. For others, it reaches limits that are determined not by the quality of the treatment but by the biological state the patient presents with.

Identifying those limits early — at assessment, or at recognisable clinical decision points during treatment — is not a failure of the approach. It is responsible practice. Patients deserve honesty about what treatment is likely to achieve in their specific case, not an optimistic framing that keeps them engaged past the point where engagement is likely to produce results.

Structural Damage Beyond Internal Correction

The most clearly defined limit of root-cause internal treatment in HS is the presence of established structural damage that cannot be reversed through systemic correction alone. This primarily applies to two categories: extensive sinus tract networks and significant fibrotic scarring.

Established Sinus Tract Networks

Sinus tracts in HS form as a consequence of repeated follicular rupture, abscess formation, and the subsequent tunnelling of inflammatory material through the dermis and subcutaneous tissue. In early and moderate disease, sinus tracts are relatively limited in extent and the surrounding tissue, while inflamed, retains some capacity for remodelling. In advanced disease — typically Hurley Stage III with extensive interconnected sinus formation — the sinus network has become a structural feature of the tissue that is not amenable to reversal through internal treatment alone.

Internal correction can reduce the inflammatory activity that sustains and extends sinus tracts, and in some cases this reduction allows partial healing at the tract margins. But it cannot remove established epithelialised tracts that have become permanent anatomical features of the affected tissue. Patients with extensive Hurley Stage III sinus tract formation should be counselled that internal treatment, even when effective at reducing systemic inflammatory drive, is unlikely to resolve the physical sinus network. Surgical intervention — specifically wide local excision — addresses what internal treatment cannot in these cases, and the combination of surgical removal with internal systemic correction to prevent recurrence in adjacent areas represents the most rational approach.

Dense Fibrotic Scarring

Fibrosis — the replacement of normal tissue architecture with dense collagen — is the end-stage consequence of repeated inflammation in HS-affected areas. Moderate fibrosis, which develops over years of recurrent disease, produces tissue that is less responsive to treatment because the normal biological environment required for tissue repair and immune regulation has been structurally replaced. Dense, established fibrosis in major HS areas represents a state of tissue change that internal correction cannot reverse — the tissue architecture that has been lost to fibrosis does not regenerate.

Internal treatment can prevent further fibrotic progression by reducing the inflammatory activity that drives ongoing fibrosis. It can improve function in the surrounding tissue that has not yet undergone complete fibrotic change. But it cannot restore the tissue that has already been replaced. Patients whose disease is characterised primarily by dense fibrosis rather than active inflammation should have realistic expectations about what internal treatment can achieve — reduced further progression rather than reversal of established change.

Metabolic States That Resist Correction

A second category of limited response involves patients whose metabolic state is so severely disrupted that the degree of internal correction achievable through systemic treatment alone is insufficient to produce meaningful HS stabilisation. HS is metabolically embedded — insulin resistance, androgen excess, and adipose-driven inflammation are not peripheral associations but active drivers of the condition. When these metabolic factors are very severely established, addressing them through internal treatment produces improvement in the metabolic state, but the degree of improvement may not reach the threshold required for HS stabilisation within a clinically reasonable timeframe.

This applies particularly to patients with severe obesity and established metabolic syndrome, where the adipose tissue itself functions as a sustained source of inflammatory signalling that internal treatment cannot fully offset. In these cases, the combination of internal treatment with structured medical weight management — potentially including surgical options where appropriate — produces more meaningful outcomes than internal treatment pursued in isolation against a metabolic environment that exceeds the corrective capacity of systemic treatment alone.

This is not a categorical exclusion of these patients from Ayurvedic treatment. It is recognition that the systemic correction achievable through any single modality has limits, and that co-management with other approaches in severe metabolic cases is not a compromise but a clinically rational response to the complexity of the patient's condition.

Patients Who Cannot Sustain the Treatment Environment

A third category of limited response involves patients who, for reasons unrelated to the treatment itself, cannot sustain the internal environment that treatment requires. This is not a criticism of those patients — it is a practical recognition that root-cause treatment depends on internal conditions that are partly under the patient's control, and that certain life circumstances make maintaining those conditions very difficult.

Chronic severe stress — of the kind produced by unresolvable life circumstances, not ordinary daily stress — maintains cortisol dysregulation, gut barrier disruption, and immune irregularity in ways that partially offset the corrections being achieved through treatment. Patients whose lives involve sustained high-intensity stress that cannot be meaningfully reduced during the treatment period will show slower and less complete responses, because one of the primary internal inflammatory drivers is being continuously reactivated.

Similarly, patients who are unable to make even partial dietary modifications — again, for legitimate reasons including economic constraints, medical dietary requirements, or other health conditions — are maintaining a gut environment that is less responsive to restoration. The degree of lifestyle alignment required for treatment to work is not absolute — meaningful improvement can occur with partial alignment — but where alignment is minimal, response will be correspondingly limited.

In these cases, the honest clinical response is to set expectations that reflect the actual treatment environment rather than the ideal one, and to identify whether there are ways to reduce the most significant modifiable obstacles rather than proceeding as if the obstacles are not present.

When to Recognise That a Limit Has Been Reached

Distinguishing between a case that requires more time and a case that has reached the limits of what internal treatment can achieve is one of the more clinically demanding judgements in managing complex HS. The risk of premature conclusion — deciding too early that a case has reached its limit and withdrawing treatment before the required internal correction has had sufficient time — is real. So is the risk of delayed conclusion — continuing treatment past the point of meaningful benefit because neither the practitioner nor the patient is ready to accept that the current approach has reached its useful boundary.

The practical markers that suggest a limit has been reached, rather than simply requiring more time, include: absence of any internal marker improvement after a reasonable treatment period with good compliance; no reduction in flare frequency or severity after eight to twelve months of sustained treatment; evidence of continued disease progression despite treatment; and structural features — extensive sinus tracts, dense fibrosis — that are not amenable to internal correction.

When these markers are present, the clinical response should be reassessment rather than continuation. Reassessment may reveal a missed driver that, once identified and addressed, changes the treatment trajectory. Or it may confirm that the current approach has delivered what it can, and that a different strategy — surgical intervention, co-management with other modalities, or a modified treatment goal focused on stability rather than reversal — is the appropriate next step.

What Remains Possible When Primary Treatment Has Limits

Even in cases where root-cause internal treatment has reached its primary limits, it does not become irrelevant. The systemic improvement achievable through internal correction — reduced overall inflammatory load, improved metabolic function, better gut health, more stable hormonal environment — continues to benefit patients even where it cannot fully reverse established structural disease.

In patients who have undergone surgical intervention for advanced disease, internal treatment plays a critical role in reducing the systemic inflammatory drive that would otherwise produce recurrence in adjacent areas. Surgery removes existing disease; internal treatment addresses the environment that would generate new disease if left uncorrected. These are complementary objectives, not competing ones.

For patients whose HS has reached a stable but not fully resolved endpoint — where significant further improvement is unlikely but the condition is no longer actively progressing — ongoing systemic support maintains the internal environment that keeps the disease stable. This is a legitimate and valuable treatment goal, even if it is different from the reversal that earlier-stage patients may achieve.